Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
作者信息
Coutre Steven, Tedeschi Alessandra, Robak Tadeusz, Barr Paul M, Owen Carolyn, Bairey Osnat, Burger Jan, Zhou Cathy, Styles Lori, James Danelle F, Kipps Thomas J
机构信息
Stanford University School of Medicine, CA, USA
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
出版信息
Haematologica. 2018 Jun;103(6):e249-e251. doi: 10.3324/haematol.2017.175380. Epub 2017 Nov 23.
Abstract
摘要
相似文献
1
Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.针对交叉情况进行生存调整：伊布替尼与苯丁酸氮芥治疗未经治疗的老年慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的3期研究
Haematologica. 2018 Jun;103(6):e249-e251. doi: 10.3324/haematol.2017.175380. Epub 2017 Nov 23.
2
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
3
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.一线伊布替尼治疗老年慢性淋巴细胞白血病患者的持续疗效和详细临床随访：RESONATE-2 扩展阶段 3 的结果。
Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.
4
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？依鲁替尼应作为标准一线治疗。
Clin Adv Hematol Oncol. 2016 May;14(5):330-3.
5
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。
Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.
6
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
7
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.伊布替尼治疗慢性淋巴细胞白血病患者完全缓解的预后因素：2 项临床试验的汇总分析。
JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.
8
A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.伊布替尼治疗慢性淋巴细胞白血病的简化预后指数：一项多中心回顾性队列研究的结果
Leuk Res. 2020 Feb;89:106302. doi: 10.1016/j.leukres.2020.106302. Epub 2020 Jan 21.
9
10
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.评估伊布替尼治疗伴有 del(11q)的慢性淋巴细胞白血病患者的长期结局的研究。
Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15.
引用本文的文献
1
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.RESONATE-2 研究 5 年随访：伊布替尼一线治疗 CLL/SLL 患者的长期疗效和安全性。
Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18.
2
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
3
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.单药伊布替尼与化疗免疫治疗方案用于初治慢性淋巴细胞白血病患者：来自 3 期临床试验的交叉试验比较。
Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.
4
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.一线伊布替尼治疗老年慢性淋巴细胞白血病患者的持续疗效和详细临床随访：RESONATE-2 扩展阶段 3 的结果。
Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.
本文引用的文献
1
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
2
Methods for adjusting for bias due to crossover in oncology trials.肿瘤学试验中针对交叉偏倚进行调整的方法。
Pharmacoeconomics. 2014 Jun;32(6):533-46. doi: 10.1007/s40273-014-0145-y.
Zotero 插件